RONALD SLIVKA: Open Payments
NPI 1265500532 · OREFIELD, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,353 in 155 payments from 16 companies in 2025. Trend: 2023 $3,120 · 2024 $2,795 · 2025 $3,353
Food & beverage: $3,353
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $594 |
| Neurocrine BioSciences, Inc. | 17 | $528 |
| Teva Pharmaceuticals USA, Inc. | 24 | $421 |
| Alkermes, Inc. | 13 | $410 |
| Otsuka America Pharmaceutical, Inc. | 15 | $376 |
| E.R. Squibb & Sons, L.L.C. | 10 | $218 |
| Janssen Pharmaceuticals, Inc | 7 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $154 |
| Collegium Pharmaceutical, Inc. | 6 | $101 |
| Lundbeck LLC | 5 | $96 |
Products named: VRAYLAR, INGREZZA, REXULTI, AUSTEDO XR, ARISTADA, COBENFY, CAPLYTA, UZEDY.
Industry payments across PA — which companies pay providers there.
